CO5300464A1 - METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN - Google Patents
METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEINInfo
- Publication number
- CO5300464A1 CO5300464A1 CO01036462A CO01036462A CO5300464A1 CO 5300464 A1 CO5300464 A1 CO 5300464A1 CO 01036462 A CO01036462 A CO 01036462A CO 01036462 A CO01036462 A CO 01036462A CO 5300464 A1 CO5300464 A1 CO 5300464A1
- Authority
- CO
- Colombia
- Prior art keywords
- sec
- protein
- ryk
- variant
- site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un método para modular la angiogénesis en el sitio, método que comprende provocar el suministro al sitio de una cantidad efectiva de una composición que comprende una proteína Ryk variante.El método de acuerdo con la reivindicación 1 en el cual la proteína Ryk variante tiene una secuencia de aminoácidos idéntica a SEC. ID. NO:2.El método de acuerdo con la reivindicación 1 en el cual la proteína Ryk variante tiene una secuencia de aminoácidos que es por lo menos 60 % idéntica a SEC. ID. NO:2 a lo largo de por lo menos 40 residuos.El método de acuerdo con la reivindicación 1 en el cual la proteína Ryk variante tiene una secuencia de aminoácidos que es por lo menos 70 % idéntica a SEC. ID. NO:2 a lo largo de por lo menos 30 residuos.Un método para modular la angiogénesis en el sitio, método que comprende provocar el suministro al sitio de una cantidad efectiva de una composición que comprende una proteína Ryk variante, donde la proteína Ryk variante tiene una secuencia de aminoácidos seleccionada entre el grupo que consiste esencialmente en SEC. ID. NO:1, SEC. ID. NO:2 y SEC. ID. NO:3.Un método para modular la formación por las células de estructuras de tipo capilar, que comprende poner en contacto a las células con una cantidad biológicamente efectiva de una composición que comprende una proteína Ryk variante, donde la proteína Ryk variante tiene una secuencia de aminoácidos seleccionada entre el grupo que consiste esencialmente en SEC. ID. NO:1, SEC. ID. NO:2 y SEC. ID. NO:3. El método de acuerdo con la reivindicación 6 en el cual las células son células endoteliales de origen humano.Una proteína que se caracteriza por tener una secuencia de aminoácidos deducida que tiene por lo menos 60% de identidad a lo largo de 40 residuos con una secuencia de aminoácidos seleccionada entre el grupo que consiste esencialmente en SEC. ID. NO:1, SEC. ID. NO:2 y SEC. ID. NO:3.A method for modulating angiogenesis at the site, a method comprising causing the delivery of an effective amount of a composition comprising a variant Ryk protein to the site.The method according to claim 1 wherein the variant Ryk protein has a sequence of amino acids identical to SEC. ID. NO: 2. The method according to claim 1 wherein the Ryk variant protein has an amino acid sequence that is at least 60% identical to SEC. ID. NO: 2 along at least 40 residues. The method according to claim 1 wherein the Ryk variant protein has an amino acid sequence that is at least 70% identical to SEC. ID. NO: 2 along at least 30 residues. A method to modulate angiogenesis at the site, which comprises causing the supply to the site of an effective amount of a composition comprising a variant Ryk protein, where the Ryk variant protein It has an amino acid sequence selected from the group consisting essentially of SEC. ID. NO: 1, SEC. ID. NO: 2 and SEC. ID. NO: 3. A method for modulating the formation of capillary-type structures by cells, which involves contacting the cells with a biologically effective amount of a composition comprising a variant Ryk protein, where the variant Ryk protein has a sequence of amino acids selected from the group consisting essentially of SEC. ID. NO: 1, SEC. ID. NO: 2 and SEC. ID. NO: 3. The method according to claim 6 in which the cells are endothelial cells of human origin.A protein characterized by having a deduced amino acid sequence that has at least 60% identity along 40 residues with a sequence of amino acids selected from the group consisting essentially of SEC. ID. NO: 1, SEC. ID. NO: 2 and SEC. ID. NO: 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56878300A | 2000-05-10 | 2000-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5300464A1 true CO5300464A1 (en) | 2003-07-31 |
Family
ID=24272718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01036462A CO5300464A1 (en) | 2000-05-10 | 2001-05-09 | METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1287121A2 (en) |
| JP (1) | JP2004527206A (en) |
| AR (1) | AR028424A1 (en) |
| AU (1) | AU2001261343A1 (en) |
| CA (1) | CA2408349A1 (en) |
| CO (1) | CO5300464A1 (en) |
| DO (1) | DOP2001000164A (en) |
| EC (1) | ECSP014068A (en) |
| GT (1) | GT200100079A (en) |
| PE (1) | PE20011218A1 (en) |
| SV (1) | SV2002000442A (en) |
| UY (1) | UY26696A1 (en) |
| WO (1) | WO2001085789A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003206854A1 (en) * | 2002-02-06 | 2003-09-02 | Developgen Aktiengesellschaft Fur Entwicklungsbiologische Forschung | Kinases involved in the regulation of energy homeostasis |
| JO3283B1 (en) | 2011-04-26 | 2018-09-16 | Sanofi Sa | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
| SG11201700284UA (en) | 2014-07-18 | 2017-02-27 | Sanofi Sa | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07506969A (en) * | 1992-05-11 | 1995-08-03 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | Molecules similar to receptor tyrosine kinases |
| CA2208319A1 (en) * | 1994-12-23 | 1996-07-04 | Ludwig Institute For Cancer Research | Assay, receptor proteins and ligands |
| AU4278299A (en) * | 1998-06-11 | 1999-12-30 | Astrazeneca Ab | Human receptor tyrosine kinase |
| CA2348835A1 (en) * | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
-
2001
- 2001-05-07 GT GT200100079A patent/GT200100079A/en unknown
- 2001-05-07 AR ARP010102149A patent/AR028424A1/en not_active Application Discontinuation
- 2001-05-08 UY UY26696A patent/UY26696A1/en not_active Application Discontinuation
- 2001-05-09 AU AU2001261343A patent/AU2001261343A1/en not_active Abandoned
- 2001-05-09 EP EP01935233A patent/EP1287121A2/en not_active Withdrawn
- 2001-05-09 SV SV2001000442A patent/SV2002000442A/en not_active Application Discontinuation
- 2001-05-09 JP JP2001582388A patent/JP2004527206A/en active Pending
- 2001-05-09 EC EC2001004068A patent/ECSP014068A/en unknown
- 2001-05-09 CO CO01036462A patent/CO5300464A1/en unknown
- 2001-05-09 WO PCT/US2001/015043 patent/WO2001085789A2/en not_active Application Discontinuation
- 2001-05-09 CA CA002408349A patent/CA2408349A1/en not_active Abandoned
- 2001-05-10 PE PE2001000417A patent/PE20011218A1/en not_active Application Discontinuation
- 2001-05-10 DO DO2001000164A patent/DOP2001000164A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR028424A1 (en) | 2003-05-07 |
| ECSP014068A (en) | 2002-02-25 |
| PE20011218A1 (en) | 2002-02-01 |
| WO2001085789A3 (en) | 2002-05-16 |
| GT200100079A (en) | 2001-12-31 |
| AU2001261343A1 (en) | 2001-11-20 |
| EP1287121A2 (en) | 2003-03-05 |
| UY26696A1 (en) | 2001-12-28 |
| DOP2001000164A (en) | 2002-05-15 |
| JP2004527206A (en) | 2004-09-09 |
| SV2002000442A (en) | 2002-07-03 |
| CA2408349A1 (en) | 2001-11-15 |
| WO2001085789A2 (en) | 2001-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021448A1 (en) | METHOD FOR PRODUCING A CHEMICAL POLYPEPTIDE | |
| AR012531A1 (en) | COMPOSITION FOR PERSONAL CARE, COMPOSITION FOR REVIEWER AND METHOD TO MINIMIZE OR REDUCE THE BEGINNING OR BURNING OF THE SKIN DUE TO COMPOSITIONS FOR PERSONAL CARE CONTAINING ACID. | |
| ES2183945T3 (en) | COMPOSITIONS TO IMPROVE THE CONTRIBUTION OF AN AGENT BY ELECTRICAL TRANSPORTATION. | |
| PE20110236A1 (en) | PROTECTION AND IMPROVEMENT OF CELLS, TISSUES AND ORGANS THAT RESPOND TO ERYTHROPOYETIN | |
| DE69628290D1 (en) | METHODS AND COMPOSITIONS FOR LIPIDIZING HYDROPHILIC MOLECULES | |
| NO992068L (en) | Microemulsion and process for its preparation | |
| DE50107705D1 (en) | NEW PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF N-0923 | |
| ATE208612T1 (en) | BIOLOGICALLY ERODABLE DEVICE FOR ADMINISTRATION OF ACTIVE INGREDIENTS | |
| ES2146552B1 (en) | INHIBITING PEPTIDES OF TGF / 31 | |
| ES2123910T3 (en) | COMPOSITIONS CONTAINING AMPHOTERAL SALTS OF ALPHA-HYDROXIACIDES AND GLYCEROL MONOCAPRILATE. | |
| BR0108734A (en) | Acid antimicrobial compositions for treating food and food contact surfaces and methods for using them | |
| ATE268386T1 (en) | PROTEASE-ACTIVABLE PSEUDOMONAS EXOTOXIN-A-LIKE PROPROTEINS | |
| AR023529A1 (en) | A HAIR CONDITIONING SHAMPOO COMPOSITION AND A METHOD FOR CONDITIONING THE HAIR | |
| ES2096872T3 (en) | ACIDIC AQUEOUS CLEANING COMPOSITIONS. | |
| BRPI0514411A (en) | formulation, and method of producing a formulation | |
| AR018357A1 (en) | PETROSELINIC ACID IN A COMPOSITION AND IN A METHOD TO REDUCE OR ELIMINATE THE IRRITATION OR THE PICAZON OF THE SKIN INDUCED BY ALFA-HYDROXIACIDES | |
| BR0009472A (en) | Lhrh antagonists with improved solubility properties | |
| DK0953576T3 (en) | Active hedgehog protein conjugate, process for its preparation and use | |
| BR0008255A (en) | Composition and process for forming stable emulsion under shear | |
| PE20030608A1 (en) | COMPOSITION AND METHOD TO TREAT DIABETES | |
| CO5300464A1 (en) | METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN | |
| ES2184300T3 (en) | DERIVATIVES OF USEFUL AMINO ACIDS TO TREAT THE ENCEPHAL VASCULAR ACCIDENT. | |
| ES2146606T3 (en) | METHOD FOR CLEANING CARPETS. | |
| AR033979A1 (en) | METHOD FOR PREPARING A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE | |
| PT1095141E (en) | METHOD FOR PRODUCING A PEPTIDE WITH A PI ABOVE 8 OR BELOW 5 |